Watch Ticker

Lyell Immunopharma, Inc. Common Stock

Go to Lyell Immunopharma, Inc. Common Stock Website

$11.37

0.35 (3.18%)

Live

Previous Close

$11.02

Day Range

$10.94 - $11.7

Previous Day Range

$11.02 - $11.665

Market Cap

$204.8 million USD

Day Vol.

32031

Previous Day Vol.

19787

Currency

USD

Primary Exchange

Nasdaq

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline include...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Prnewswire - Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments

Several biotech companies are developing innovative cancer treatments, with promising clinical trial results in various cancer types, focusing on immunotherapy and personalized medicine approaches.

Related tickers: ONCY, CELC, LYEL, EVAX, AGEN.

Read Full Article

N/A - Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

Lyell Immunopharma announced positive clinical data for its lead product candidate LYL314, an autologous dual-targeting CD19/CD20 CAR T-cell therapy, in the treatment of relapsed and/or refractory large B-cell lymphoma. The data showed high rates of durable complete responses in patients treated in the third- or later-line setting.

Related tickers: LYEL.

Read Full Article

Trending Tickers

Please sign in to view